TABLE 1.
Baseline demographic characteristics of 91 lung cancer patients.
| Characteristic | Group C (N = 49) | Group BP‐1 (N = 42) | p‐value |
|---|---|---|---|
| Age (year), mean (SD) | 60.06 (7.67) | 58.95 (8.51) | 0.515 |
| Gender, n (%) | |||
| Male | 33 (67.35) | 30 (71.43) | 0.674 |
| Female | 16 (32.65) | 12 (28.57) | |
| Ethnicity, n (%) | |||
| Han | 48 (97.96) | 41 (97.62) | 1.000 |
| Other | 1 (2.04) | 1 (2.38) | |
| History of allergy, n (%) | |||
| No | 49 (100.00) | 42 (100.00) | ‐ |
| History of significant past, n (%) | |||
| No | 49 (100.00) | 42 (100.00) | ‐ |
| Stage, n (%) | 0.249 | ||
| I | 12 (24.49) | 6 (14.29) | |
| II | 8 (16.33) | 14 (33.33) | |
| III | 19 (38.78) | 15 (35.71) | |
| IV | 10 (20.41) | 7 (16.67) | |
| History of surgery, n (%) | |||
| Yes | 27 (55.10) | 25 (59.52) | 0.671 |
| No | 22 (44.90) | 17 (40.48) | |
| Performance status, n (%) | |||
| 0 | 40 (81.63) | 32 (76.19) | 0.524 |
| 1 | 9 (18.37) | 10 (23.81) | |
| Chemotherapy regimen | |||
| Pemetrexed + carboplatin | 19 (38.78) | 16 (38.10) | 0.680 |
| Pemetrexed + cisplatinum | 6 (12.24) | 7 (16.67) | |
| Etoposide + cisplatinum | 5 (10.20) | 7 (16.67) | |
| Gemcitabine + cisplatinum | 2 (4.08) | 1 (2.38) | |
| Paclitaxel + carboplatin | 7 (14.29) | 7 (16.67) | |
| Paclitaxel + cisplatinum | 10 (20.41) | 4 (9.52) | |
Abbreviations: SD, standard deviation.